RenovoRx Statistics
Share Statistics
RenovoRx has 24.00M shares outstanding. The number of shares has increased by 124.31% in one year.
| Shares Outstanding | 24.00M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.15% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 23.54M |
| Failed to Deliver (FTD) Shares | 16.28K |
| FTD / Avg. Volume | 27.37% |
Short Selling Information
The latest short interest is 71.85K, so 0.3% of the outstanding shares have been sold short.
| Short Interest | 71.85K |
| Short % of Shares Out | 0.3% |
| Short % of Float | 0.31% |
| Short Ratio (days to cover) | 3.43 |
Valuation Ratios
The PE ratio is -2.3 and the forward PE ratio is -2.8.
| PE Ratio | -2.3 |
| Forward PE | -2.8 |
| PS Ratio | 0 |
| Forward PS | 1.1 |
| PB Ratio | -7.86 |
| P/FCF Ratio | -2.3 |
| PEG Ratio | n/a |
Enterprise Valuation
RenovoRx Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 1.25, with a Debt / Equity ratio of 0.
| Current Ratio | 1.25 |
| Quick Ratio | 1.25 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | -105.52 |
Financial Efficiency
Return on equity (ROE) is 3.41% and return on capital (ROIC) is 379.87%.
| Return on Equity (ROE) | 3.41% |
| Return on Assets (ROA) | -6.98% |
| Return on Capital (ROIC) | 379.87% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.28M |
| Employee Count | 8 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 48.54% in the last 52 weeks. The beta is 0.99, so RenovoRx 's price volatility has been higher than the market average.
| Beta | 0.99 |
| 52-Week Price Change | 48.54% |
| 50-Day Moving Average | 1.11 |
| 200-Day Moving Average | 1.2 |
| Relative Strength Index (RSI) | 55.61 |
| Average Volume (20 Days) | 59.49K |
Income Statement
In the last 12 months, RenovoRx had revenue of $0 and earned -$10.23M in profits. Earnings per share was $-0.99.
| Revenue | 0 |
| Gross Profit | 0 |
| Operating Income | -11.40M |
| Net Income | -10.23M |
| EBITDA | -11.40M |
| EBIT | - |
| Earnings Per Share (EPS) | -0.99 |
Balance Sheet
The company has $1.17M in cash and $0 in debt, giving a net cash position of $1.17M.
| Cash & Cash Equivalents | 1.17M |
| Total Debt | 0 |
| Net Cash | 1.17M |
| Retained Earnings | -41.41M |
| Total Assets | 10.03M |
| Working Capital | 8.26M |
Cash Flow
In the last 12 months, operating cash flow was -$10.26M and capital expenditures $0, giving a free cash flow of -$10.26M.
| Operating Cash Flow | -10.26M |
| Capital Expenditures | 0 |
| Free Cash Flow | -10.26M |
| FCF Per Share | -1 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
RNXT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -77.95% |
| FCF Yield | -33.65% |
Analyst Forecast
The average price target for RNXT is $6.5, which is 411.8% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $6.5 |
| Price Target Difference | 411.8% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
Scores
| Altman Z-Score | -2.46 |
| Piotroski F-Score | 2 |